Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection

被引:0
作者
Devrim, Ilker [1 ]
Devrim, Fatma [2 ]
Bayram, Nuri [1 ]
Akturk, Huseyin [1 ]
Aksay, Ahu [1 ]
Can, Demet [3 ]
Apa, Hursit [1 ]
机构
[1] Dr Behcet Uz Childrens Hosp, Dept Pediat Infect Dis, Izmir, Turkey
[2] Dr Behcet Uz Childrens Hosp, Dept Pediat, Izmir, Turkey
[3] Dr Behcet Uz Childrens Hosp, Izmir, Turkey
来源
MINERVA PEDIATRICS | 2021年 / 73卷 / 02期
关键词
Isoniazid; Child; Tuberculosis; RISK-FACTORS; ANTITUBERCULOSIS DRUGS; PYRAZINAMIDE; RIFAMPIN; THERAPY;
D O I
10.23736/S2724-5276.17.04338-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BACKGROUND: We aimed to determine overall incidence of severe and mild isoniazid (INH) hepatotoxicity and outcome of hepatotoxicity in children who were receiving INH for latent tuberculosis. METHODS: Patients who had received isoniazid for treatment of latent tuberculosis were included in the study. Hepatotoxicity was classified according to the World Health Organization Toxicity Classification Standards. RESULTS: Among 1038 patients, overall hepatotoxicity was observed in 22 patients (2.2%), while 5 patients (0.48%) had moderate-severe hepatotoxicity; while other 17 patients had grade I-II hepatotoxicity (1.63%). Age and gender did not appear to be risk factors for hepatotoxicity. The median time for therapy rechallenge in patients with grade III-IV hepatotoxicity was 21 days (ranging from 14 to 25 days). CONCLUSIONS: Isoniazid hepatotoxicity is lower and generally reversible after cessation of INH in children. The grade of hepatotoxicity affects the duration for recovery of hepatotoxicity and restarting of INH therapy.
引用
收藏
页码:184 / 187
页数:4
相关论文
共 19 条
[1]  
CDC, LAT TUB INF GUID PRI
[2]   Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection [J].
Chang, Shiow-Huey ;
Nahid, Payam ;
Eitzman, Sarah R. .
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2014, 3 (03) :221-227
[3]   Risk Factors for Isoniazid Hepatotoxicity in Children With Latent TB and TB: Difference From Adults [J].
Devrim, Ilker ;
Olukman, Oezguer ;
Can, Demet ;
Dizdarer, Ceyhun .
CHEST, 2010, 137 (03) :737-738
[4]   Antituberculosis drug- induced hepatotoxicity in children [J].
Donald, Peter R. .
PEDIATRIC REPORTS, 2011, 3 (02) :51-64
[5]   Liver injury during antituberculosis treatment: An 11-year study [J].
Dossing, M ;
Wilcke, JTR ;
Askgaard, DS ;
Nybo, B .
TUBERCLE AND LUNG DISEASE, 1996, 77 (04) :335-340
[6]   Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection - A 7-year evaluation from a public health tuberculosis clinic [J].
Fountain, FF ;
Tolley, E ;
Chrisman, CR ;
Self, TH .
CHEST, 2005, 128 (01) :116-123
[7]   Use of isoniazid for latent tuberculosis infection in a public health clinic [J].
LoBue, PA ;
Moser, KS .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (04) :443-447
[8]   Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis - Improved completion rates but more hepatotoxicity [J].
McNeill, L ;
Allen, M ;
Estrada, C ;
Cook, P .
CHEST, 2003, 123 (01) :102-106
[9]   Hepatotoxicity associated with isoniazid preventive therapy - A 7-year survey from a public health tuberculosis clinic [J].
Nolan, CM ;
Goldberg, SV ;
Buskin, SE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (11) :1014-1018
[10]   Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients [J].
Ohkawa, K ;
Hashiguchi, M ;
Ohno, K ;
Kiuchi, C ;
Takahashi, S ;
Kondo, S ;
Echizen, H ;
Ogata, H .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (02) :220-226